Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
29
09
2021
accepted:
27
06
2022
revised:
14
06
2022
pubmed:
15
7
2022
medline:
7
10
2022
entrez:
14
7
2022
Statut:
ppublish
Résumé
Measurable residual disease (MRD) assessment before allogeneic hematopoietic cell transplantation (HCT) may help physicians to identify a subgroup of patients at high risk of relapse for de novo acute myeloid leukemia (AML) but its relevance among patients affected by secondary AML (sAML) is still unknown. We assessed the impact of MRD among 318 adult patients with sAML who received an allogeneic HCT in first complete remission. At the time of HCT, a total of 208 (65%) patients achieved MRD negativity, while 110 (35%) had positive MRD. 2-year overall survival (OS) was 58.8 % (95% CI 52.2-64.9) with leukemia-free survival (LFS) of 50.0 % (95% CI 43.7-56.1), relapse incidence of 34.2% (95% CI 28.4-40.1) and non-relapse mortality (NRM) of 23.3 % (95% CI 19-27.7) for the entire cohort. In multivariate analysis, HCT recipients with KPS ≥ 90 experienced less disease recurrence (HR 0.61, 95% CI 0.4-0.94) with better LFS (HR 0.63, 95% CI 0.44-0.89) and OS (HR 0.58, 95% CI 0.39-0.86). There were no differences in major clinical endpoints between patients with MRD-positive and MRD-negative status at the time of HCT. Pre-transplantation assessment of MRD was not informative on post-HCT outcomes in this retrospective registry-based analysis among patients affected by sAML.
Identifiants
pubmed: 35835997
doi: 10.1038/s41409-022-01748-w
pii: 10.1038/s41409-022-01748-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1556-1563Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Brüggemann M, Raff T, Flohr T, Gokbuget N, Nakao M, Droese J, et al. German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116–23.
pubmed: 16195338
doi: 10.1182/blood-2005-07-2708
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153–62.
pubmed: 19141862
doi: 10.1182/blood-2008-11-185132
Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14:199–209.
pubmed: 23395119
doi: 10.1016/S1470-2045(12)70600-9
Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6:1890–9.
pubmed: 33030517
pmcid: 7545346
doi: 10.1001/jamaoncol.2020.4600
Kohlmann A, Nadarajah N, Alpermann T, Grossmann V, Schindela S, Dicker f, et al. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. Leukemia. 2014;1:129–37.
doi: 10.1038/leu.2013.239
Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189–99.
pubmed: 29601269
doi: 10.1056/NEJMoa1716863
Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275–91.
pubmed: 29330221
pmcid: 5865231
doi: 10.1182/blood-2017-09-801498
Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889–97.
pubmed: 24062400
doi: 10.1200/JCO.2012.45.9628
Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children’s Oncology Group. Blood. 2012;120:1581–8.
pubmed: 22649108
pmcid: 3429302
doi: 10.1182/blood-2012-02-408336
Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, et al. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol. 2018;36:1486–97.
pubmed: 29601212
pmcid: 5959196
doi: 10.1200/JCO.2017.76.3425
Freeman SD, Virgo P, Couzens S, Grimwade D, Russel N, Hills RK, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013;31:4123–31.
pubmed: 24062403
doi: 10.1200/JCO.2013.49.1753
Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Griesinger F, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol. 2006;24:3686–92.
pubmed: 16877738
doi: 10.1200/JCO.2005.05.4312
Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A.UK National Cancer Research Institute AML Working Group et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422–33.
pubmed: 26789727
doi: 10.1056/NEJMoa1507471
Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102:865–73.
pubmed: 28126965
pmcid: 5477605
doi: 10.3324/haematol.2016.159343
Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29:1190–7.
pubmed: 21282535
pmcid: 3083874
doi: 10.1200/JCO.2010.31.8121
Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, et al. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group. J Clin Oncol. 2017;35:185–93.
pubmed: 28056203
doi: 10.1200/JCO.2016.67.1875
Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol. 2018;93:1142–52.
pubmed: 29981272
doi: 10.1002/ajh.25211
Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. 2012;120:468–72.
pubmed: 22517895
pmcid: 3398757
doi: 10.1182/blood-2012-02-409813
Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, et al. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 2017;102:110–7.
pubmed: 27540139
pmcid: 5210241
doi: 10.3324/haematol.2016.144253
Ustun C, Wiseman AC, Defor TE, Yohe S, Linden MA, Oran B, et al. Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transpl. 2013;48:1415–20.
doi: 10.1038/bmt.2013.124
Anthias C, Dignan F, Morilla R, Morilla A, Ethell ME, Potter MN, et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transpl. 2014;49:679–83.
doi: 10.1038/bmt.2014.9
Canaani J, Labopin M, Huang XJ, Ciceri F, Van Lint MT, Bruno B, et al. Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T‐cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Br J Hematol. 2018;183:411–20.
doi: 10.1111/bjh.15540
Othus M, Wood BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR, et al. Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. Leukemia. 2016;30:2080–3.
pubmed: 27133827
pmcid: 5053842
doi: 10.1038/leu.2016.120
Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 2015;33:1258–64.
pubmed: 25732155
doi: 10.1200/JCO.2014.58.3518
Gilleece MH, Shimoni A, Labopin M, Robinson S, Beelen D, Sociè G, et al. Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT. Blood Cancer J. 2021;11:88.
pubmed: 33980810
pmcid: 8116335
doi: 10.1038/s41408-021-00479-3
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.
Granfeldt Østgård LS, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33:3641–9.
pubmed: 26304885
doi: 10.1200/JCO.2014.60.0890
Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117:2137–45.
pubmed: 21127174
doi: 10.1182/blood-2010-08-301713
Schmaelter AK, Labopin M, Socié G, Itälä-Remes M, Blaise D, Yakoub-Agha I, et al. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J. 2020;10:1–9.
doi: 10.1038/s41408-020-0296-3
Ciurea S, Labopin M, Sociè G, Volin L, Passweg J, Chevalier P, et al. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: a report from the acute leukemia working party of the European society for blood and marrow transplantation and the university of Texas MD Anderson cancer center. Cancer 2018;124:2134–41.
pubmed: 29469961
doi: 10.1002/cncr.31311
Kanate AS, Nagler A, Savani BN. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic. Cell Transplant Clin Hematol Int. 2020;2:2–4.
pubmed: 34595436
doi: 10.2991/chi.d.191207.001
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–55.
doi: 10.1016/j.bbmt.2005.09.004
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.
Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission. Bone Marrow Transpl. 2016;51:610–1.
doi: 10.1038/bmt.2015.305
Nagler A, Baron F, Labopin M, Polge E, Esteve J, Bazarbachi A, et al. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transpl. 2021;56:218–24.
doi: 10.1038/s41409-020-01005-y
Tazi Y, Arango JE, Zhou Y, Thomas I, Bernard E, Gilkes A, et al. A unified classification and risk stratification algorithm to support clinical decisions in acute myeloid leukemia. Haematologica. 2021;406-4:S133.
Morsink LM, Othus M, Bezerra ED, Wood BL, Fang M, Sandmaier BM, et al. Impact of pre-transplant measurable residual disease on outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. Leukemia. 2020;34:1577–87.
pubmed: 31974434
pmcid: 7272254
doi: 10.1038/s41375-020-0717-0
Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004;18:120–5.
pubmed: 14586477
doi: 10.1038/sj.leu.2403187
Ornstein MC, Mukherjee S, Mohan S, Elson P, Tiu RV, Saunthararajah Y, et al. Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia. Am J Hematol. 2014;89:168–73.
pubmed: 24123154
doi: 10.1002/ajh.23605
Stölzel F, Pfirrmann M, Aulitzky WE, Kaufmann M, Bodenstein H, Bornhäuser M, et al. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. Leukemia 2011;25:420–8.
pubmed: 21135859
doi: 10.1038/leu.2010.279
Kröger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009;94:542.
pubmed: 19278968
pmcid: 2663618
doi: 10.3324/haematol.2008.000927
Sengsayadeth S, Labopin M, Boumendil A, Finke J, Ganser A, Stelljes M, et al. Transplant outcomes for secondary acute myeloid leukemia: acute leukemia working party of the european society for blood and bone marrow transplantation study. Biol Blood Marrow Transpl. 2018;24:1406–14.
doi: 10.1016/j.bbmt.2018.04.008
Fianchi L, Pagano L, Piciocchi A, Candoni A, Gaidano G, Breccia M, et al. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol. 2015;90:E80–5.
pubmed: 25653205
doi: 10.1002/ajh.23966
Saraceni F, Labopin M, Forcade E, Kroger N, Socié G, Niittyvuopio R, et al. Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer Med. 2021;10:23–33.
pubmed: 33242374
doi: 10.1002/cam4.3593
Carrè M, Poercher R, Finke J, Ehninger G, Koster L, Beelen D, et al. Role of age and hematopoietic cell transplantation-specific comorbidity index in myelodysplastic patients. Biol Blood Marrow Transpl. 2020;3:451–7.
doi: 10.1016/j.bbmt.2019.10.015
Wedding U, Röhrig B, Klippstein A, Fricke HJ, Sayer HG, Höffken K. Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol. 2006;132:665.
pubmed: 16821071
doi: 10.1007/s00432-006-0115-7
Deschler B, Binek K, Ihorst G, Marks R, Wasch R, Bertz H, et al. Prognostic factor and quality of life analysis in 160 patients aged > or =60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2010;16:967–75.
doi: 10.1016/j.bbmt.2010.02.004
Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol. 2009;27:61–69.
pubmed: 19047294
doi: 10.1200/JCO.2007.15.4245
Kyriakou C, Boumendil A, Finel H, Schmitz N, Andersen NS, Blaise D, et al. The impact of advanced patient age on mortality after allogeneic hematopoietic cell transplantation for non-hodgkin lymphoma: a retrospective study by the European society for blood and marrow transplantation lymphoma working party. Biol Blood Marrow Transpl. 2019;25:86–93.
doi: 10.1016/j.bbmt.2018.08.025
Muffly L, Pasquini MC, Martens MC, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130:1156–64.
pubmed: 28674027
pmcid: 5580273
doi: 10.1182/blood-2017-03-772368
Ringden O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients age >69 years with acute myelogenous leukemia: on behalf of the acute leukemia working party of the European society for blood and marrow transplantation. Biol Blood Marrow Transpl. 2019;25:1975–83.
doi: 10.1016/j.bbmt.2019.05.037
Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, et al. Cord-blood transplantation in patients with minimal residual disease. N Eng J Med. 2016;375:944–55.
doi: 10.1056/NEJMoa1602074
Morsink LM, Sandmaier BM, Othus M, Palmieri R, Granot N, Bezerra ED, et al. Conditioning intensity, pre-transplant flow cytometric measurable residual disease, and outcome in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Cancers. 2020;12:2339.
pmcid: 7565021
doi: 10.3390/cancers12092339
Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of Allogeneic Transplantation for acute myeloid leukemia with Genomic evidence of residual disease. J Clin Oncol. 2021;38:1273–84.
doi: 10.1200/JCO.19.03011
Liu FJ, Cheng WY, Lin XJ, Wang SY, Jiang TY, Ma TT, et al. Measurable residual disease detected by multiparameter Flow Cytometry and Sequencing improves prediction of Relapse and survival in Acute Myeloid Leukemia. Front Oncol. 2021;11:677833. https://doi.org/10.3389/fonc.2021.677833 .
doi: 10.3389/fonc.2021.677833
pubmed: 34094982
pmcid: 8173083
Brooimans RA, van der Velden VHJ, Boeckx N, Boeckx N, Slomp J, Preijers F, et al. Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: is multicentric MRD assessment feasible? Leuk Res. 2019;76:39–47.
pubmed: 30553189
doi: 10.1016/j.leukres.2018.11.014
Paras G, Morsink LM, Othus M, Milano F, Sandmaier B, Zarling LC, et al. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood. 2022;139:1694–706.
pubmed: 34995355
doi: 10.1182/blood.2021014804
Zhou Y, Othus M, Walter RB, Estey EH, Wu D, Wood BL, et al. Deep NPM1 sequencing following allogeneic hematopoietic cell transplantation improves risk assessment in adults with NPM1-mutated AML. Biol Blood Marrow Transpl. 2018;24:1615–20.
doi: 10.1016/j.bbmt.2018.04.017
Lesieur A, Thomas X, Nibourel O, Boissel N, Fenwarth L, De Botton S, et al. Minimal Residual Disease monitoring in acute myeloid leukemia with non A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use. Haematologica. 2021;106:1767–9.
pubmed: 33299234
doi: 10.3324/haematol.2020.260133
Mannina D, Badbaran A, Wolschke C, Klyuchnikov E, Christopeit M, Fehse B, et al. Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis. Bone Marrow Transpl. 2022;57:510–2.
doi: 10.1038/s41409-022-01566-0
Levine RL, Valk PJM. Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia. Haematologica 2019;104:868–71.
pubmed: 30923100
pmcid: 6518900
doi: 10.3324/haematol.2018.205955
Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132:1703–13.
pubmed: 30190321
doi: 10.1182/blood-2018-02-829911
Kim T, Moon JH, Ahn JS, Kim YK, Lee SS, Ahn SY, et al. Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. Blood. 2018;132:1604–13.
pubmed: 30108064
doi: 10.1182/blood-2018-04-848028